ALZN
Alzamend Neuro, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.66
−2.35%Next report
Analyst consensus
- Next report date
- Sep 9, 2026
- EPS estimate
- -$0.56
- Revenue estimate
- —
Latest reported
- Last report date
- Mar 11, 2026
- EPS actual
- -$0.58
- EPS estimate
- -$0.53
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +38.6%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 9, 2026